Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case Report

Unusual Pattern of Arterial Macrothrombosis Causing Stroke in a Young Adult Recovered from COVID-19

Ashkan Mowla, MD,* Saman Sizdahkhani, MD,* Maryam Sharifian-Dorche, MD,† Prad Selvan, MD,* Benjamin A. Emanuel, MD,‡ Matthew S. Tenser, MD,* Arun P. Amar, MD,* and William J. Mack, MD*

Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Neurological manifestations related to COVID-19, including acute ischemic stroke (AIS), have been reported in recent studies. In most of these, the patients are older, have multiple co-morbidities as risk factors for AIS and have developed a severe respiratory illness. Herein, we report a 36-year-old man with no significant past medical history who recently recovered from a mild COVID-19 infection and presented with unusual pattern of arterial macrothrombosis causing AIS. When the AIS happened, he had no COVID-19 related symptoms, had two negative screening tests for the infection and his chest CT was unremarkable.

Key Words: Coronavirus disease-19—COVID—Large Vessel Occlusion—Acute Ischemic Stroke—Young—Macrothrombosis—SARS-CoV-2 Infection

Introduction

Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Symptoms vary from none to mild common cold symptoms, fever, diarrhea, myalgia, and cough which can progress to acute respiratory distress syndrome, multisystem organ failure, and death. Neurological sequelae have also been reported in addition to the pulmonary symptoms. Neurological symptoms range from mild headache, dizziness, and anosmia to more severe complications such as thrombotic stroke, a finding reported in 1–3% of patients.1,2 To date, several patients presenting with AIS during active COVID-19 infection have been reported. However, most of these patients had significant co-morbidities and established cardiovascular risk factors, making it difficult to confirm COVID-19 as the precipitating cause.3 While coagulopathy and vascular endothelial dysfunction have been widely reported as a consequence of severe COVID-19 infection, these findings are proposed to be directly related to the severity of the respiratory illness,4 and the prevalence of this prothrombotic state among milder or asymptomatic cases is not yet established.

Herein, we report an unusual pattern of arterial macrothrombosis presenting as large vessel stroke in a 36-year-old patient with no prior medical history (PMH) who had recently recovered from a mild COVID-19 infection. In addition to his lack of conventional stroke risk factors except for mildly elevated Hemoglobin A1c and elevated low-density lipoprotein (LDL) cholesterol, the case is unique in the temporal association of stroke occurring in the post-symptomatic phase of infection.

Abbreviations: COVID-19, Coronavirus disease-19; AIS, Acute Ischemic Stroke; PMH, Past Medical History; NIHSS, National Institutes of Health Stroke Scale; CT, Computed Tomography; CTA, CT Angiography; ASPECT, Alberta Stroke Program Early CT, MCA, Middle Cerebral Artery; ECA, External Carotid Artery; ICA, Internal Carotid Artery; LVO, Large Vessel Occlusion; PCR, Polymerase Chain Reaction; TICI, Thrombolysis in Cerebral Infarction

From the *Department of Neurological Surgery, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA 90007, USA; †Departments of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada; and ‡Department of Neurology, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA 90007, USA.

Received August 2, 2020; revision received August 20, 2020; accepted September 17, 2020.

Corresponding author. E-mail: mowla@usc.edu.
1052-3057/$ - see front matter © 2020 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105353
Case Description

A previously healthy 36-year-old male who had recently recovered from a mild case of COVID-19 infection presented to the emergency department with acute onset of left hemiparesis, left visual hemi-neglect and dysarthria 10 hours after symptom onset. Ten days prior to this, he was diagnosed with COVID-19 via nasopharyngeal swab and reverse transcription polymerase chain reaction (rtPCR). At the time of COVID-19 diagnosis, his symptoms included mild fever, myalgias and three days of diarrhea. Prior to this, the patient had no significant PMH and was not taking any medications. Throughout his illness he never experienced any respiratory symptoms. The patient had complete resolution of his COVID-19 symptoms several days prior to admission for stroke symptoms. Furthermore, COVID-19 testing, via nasopharyngeal swab and PCR was performed at the presenting emergency department as well as at the accepting hospital and were all negative. Computed tomography of the head (CTH) and angiography (CTA) of head and neck showed a large sub-occlusive thrombus in the right common carotid bifurcation extending to both internal (ICA) and external carotid arteries (ECA). The patient was loaded with Aspirin 325mg, started on heparin infusion and transferred to our center for treatment.

Upon arrival, 12 h after symptom onset, he had right middle cerebral artery (MCA) syndrome with a National Institute of Health Stroke Scale (NIHSS) score, a measure of stroke severity based on neurological exam, of 12 (range 0–42).

At our center, CTA head and neck, CT perfusion of brain and CTH revealed a right MCA (anterior M2 segment) occlusion with significant perfusion mismatch in right MCA territory in addition to the CTA neck findings. He had an Alberta Stroke Program Early CT (ASPECT) score of 8 (range 0–10) on CTH. Given the disabling neurological symptoms with significant perfusion mismatch in the right MCA territory, the decision was made to proceed with mechanical thrombectomy.

In the cervical right common carotid angiogram, a large amount of sub-occlusive thrombus was noted in the right carotid bulb and proximal ICA with extension into the proximal right ECA (Fig. 1). A Walrus balloon guide catheter (Q’Apel Medical, Fremont, CA) was advanced under fluoroscopy via femoral arteriotomy to the distal common carotid artery and inflated to cause flow arrest. Direct aspiration was then performed using a large bore catheter positioned within the proximal ICA and carotid bulb clot. A large amount of clot was suctioned and subsequent angiogram demonstrated resolution of thrombus within the carotid bulb and proximal ICA. Of note, some thrombus was still present within the proximal ECA (Fig. 2). We then proceed with mechanical thrombectomy of the occluded right anterior M2 segment (Fig. 3). Following a total of three stent retrieval pulls using the Solitaire X
procedure which did not show any intracerebral hemorrhage. Heparin drip and Aspirin 81 mg daily were continued due to the patient’s massive thrombus and clinical hypercoagulable state associated with recent COVID-19 infection.

Given his recent COVID-19 infection history, a chest CT was performed which was unremarkable. Magnetic resonance imaging (MRI) of the brain was performed 24 h later which demonstrated a large acute infarct in the right MCA territory with only minor petechial bleed, despite complete recanalization. A full stroke workup, including electrocardiogram, telemetry during hospital admission, echocardiography, and blood work for evaluation of underlying inherited coagulation disorder were performed which were all unremarkable. In his transthoracic echocardiogram with bubble study, no right-to-left shunting was detected, ejection fraction was 65% and there was no evidence of left ventricular hypertrophy. However, his labs were notable for elevated CRP and D-Dimer, signifying a persistent procoagulant/proinflammatory state (Table 1). Patient’s weight was 67.3 kg and body mass index was 23.3 kg/m². He had no family or personal history of stroke and no history of tobacco use. The patient’s neurological symptoms did not significantly improve during hospitalization and he was transferred to an acute rehabilitation unit (ARU) where he regained some strength in his previously flaccid left hemi-body. Modified Rankin Scale on discharge to ARU was 4.

Discussion

AIS with COVID-19 infection has been recently reported in 1 to 30 days following onset of respiratory symptoms. Rate of stroke in COVID-19 patients is 1–3% depending on the severity of the COVID-19 illness.1–3,9,10 Our patient characteristics and imaging findings were notable for the following aspects:

Young Age

The majority of COVID-19 patients with large vessel stroke reported thus far were older with underlying comorbidities and conventional cardiovascular risk factors. Here, the patient’s young age with no PMH supports the idea that his stroke might have been associated with his recent COVID-19 infection. Of the reported large vessel strokes, few were in young adults without any underlying cardiovascular risk factors, comorbidities or history of thrombophilia. Oxley T et al.5 described five COVID-19 patients, aged 33–49 years old, with large vessel stroke. The proposed mechanisms for stroke in this group of patients include involvement of endothelial and neutrophil extracellular traps as well as coagulopathy.6,9 Our patient is among the few reported cases who fall under this category given his young age, lack of comorbidities or cardiovascular risk factors except for mildly elevated
Hemoglobin A1c and elevated LDL cholesterol, and his negative inherited thrombophilia screen.

*Mild COVID-19 infection*

There is strong evidence to support development of coagulation abnormalities and rise in procoagulant factors in patients with COVID-19 infection. However, these findings are reported far more in patients with severe pulmonary disease. Our patient had completely recovered from COVID-19 symptoms at the time presentation and never manifested pulmonary symptoms or pathology on his chest CT, which might suggest the presence of coagulopathy and endothelial dysfunction even in the absence of severe disease. This may be attributable to viral involvement of the endothelium.

*ECA involvement*

The common carotid artery angiogram of our patient showed an extensive amount of sub-occlusive thrombus in the carotid bulb with extension into the proximal internal carotid artery and ECA (Fig. 1) in addition to an MCA occlusion. Such extensive thrombus in the ECA occur uncommonly in AIS patients and were not reported in the prior COVID-19 patients with large vessel stroke.

**Table 1. Laboratory Findings**

| Laboratory Test                              | Patient’s Lab Results | Normal Ranges          |
|----------------------------------------------|-----------------------|------------------------|
| White blood cell count per mm³               | 9740                  | 5,000 – 10,000/mm³     |
| Neutrophils                                  | 87%                   | 45–75% of total white blood cells |
| Lymphocytes                                  | 8.5 %                 | 18–45% of total white blood cells |
| Platelet count per mm³                       | 569000                | 150 000–450 000/mm³    |
| Hemoglobin g/dL                              | 14.1                  | 13.8–17.2 g/dL         |
| Albumin g/dL                                 | 3.7                   | 3.4–5.4 g/dL           |
| Alanine aminotransferase U/L                 | 40                    | 7–55 U/L               |
| Aspartate aminotransferase U/L               | 19                    | 6–34 IU/L              |
| Lactate dehydrogenase U/L                    | 232                   | 140 U/L – 280 U/L      |
| Cardiac Troponin T ng/mL                     | <0.010                | 0–0.4 ng/mL            |
| Prothrombin Time-sec                         | 14.1                  | 11.0–12.5 s            |
| Activated partial thromboplastin time -sec   | 31.4                  | 25–35 seconds          |
| D-Dimer ng/ml                                | 649                   | <250 ng/mL             |
| Ferritin ng/ml                               | 420                   | 20–250 ng/mL           |
| C-reactive protein mg/L                      | 11.7                  | <10 mg/L               |
| Homocysteine μmol/L                          | 6.9                   | <15 μmol/L             |
| Hemoglobin A1C                               | 6.2 %                 | <5.7%                  |
| Low-Density Lipoprotein mg/dL                | 152                   | <129 mg/dL             |
| Drug screen test (blood)                     | Negative              |                        |
| Activated protein C                          | Normal                |                        |
| Factor V Leiden                              | Negative              |                        |
| Factor 2 level                               | Normal                |                        |
| Lupus Anticoagulant                          | Negative              |                        |
| Blood Gas Findings on arrival                |                       |                        |
| pH                                           | 7.33                  | 7.35–7.45              |
| Pco2                                         | 40                    | 35–45 mmHg.            |
| Po2                                          | 110                   | 80–100 mmHg.           |

*Negative COVID-19 status*

To date, all the reported large vessel strokes in young adults attributed to COVID-19 infection have been in patients with at least mild symptoms of COVID-19 infection with positive PCR at the time of stroke. Our patient is different since he clinically recovered from his mild COVID-19 symptoms days prior to the stroke and had 2 negative PCR tests on the day stroke occurred. This finding is unique and may suggest a continued procoagulant state with endothelial involvement even after resolution of COVID-19 symptoms.

**Outcome**

Despite swift and successful recanalization in this patient with significant mismatch on perfusion imaging, he had a devastating prognosis and functional outcome. This is in line with the outcome of other young COVID-19 patients with large vessel stroke reported thus far displaying poor prognosis. Delay in seeking care and subsequently delayed treatment due to fear and concerns about going to a hospital during the pandemic have been reported repeatedly and may have contributed to the poor outcome of these patients; however, re-occlusion of the recanalized vessels might have developed by the procoagulant state, an association that has already been
UNUSUAL PATTERN OF ARTERIAL MACROTHROMBOSIS CAUSING STROKE

in addition, significant neurological deficits with NIHSS score of 12 at presentation and presence of some established ischemic changes on initial head CT with ASPECT score of 8 are the other potential contributors to poor outcome in our patient.

In conclusion, we report a young adult with no underlying comorbidities who recently recovered from COVID-19 infection and presented with AIS due to multicentric large vessel occlusion. He had salvageable penumbra and underwent successful mechanical thrombectomy but infarcted nonetheless and unfortunately remained with poor functional outcome. Our patient had very mild COVID-19 related symptoms which had resolved at the time of stroke presentation, approximately ten days after his initial COVID-19 screening test. In addition, he had two negative PCR test on the day of admission for stroke. Although our understanding of COVID-19 pathophysiology in the CNS vasculature and its role in morbidity and mortality is still in its infancy, acquired thrombophilia and endothelial dysfunction have been proposed as the potential mechanisms of AIS in these patients. Our findings also suggest the possibility of a prolonged and continued procoagulant state even after resolution of symptoms from the infection, a characteristic which also potentiates the risk for re-occlusion of the recanalized vessels. The poor outcome of our patient may also be partially attributable to the delay in seeking appropriate care in light of the current climate of fear for the hospital. Lastly, our case had both intracranial and extracranial large vessel occlusion with an unusual pattern of macrothrombosis of the proximal ECA, not previously reported.

Declaration of Competing Interest

APA reports the following: Consultant to Medtronic Neurovascular and Valencia Technologies WJM reports the following: consultant: Rebound Therapeutics, Viseon Imperative Care, Q’Apel, Medtronic, Stryker, Stream Biomedical, Spartan Micro; Investor: Cerebrotech, Endostream, Viseon, Rebound, Q’Apel, and Spartan Micro Other coauthors report no conflict of interest.

Authors Roles

Ashkan Mowla: Responsible for study design, Literature review, Drafting of the initial manuscript, Critical revising for intellectual content; Saman Sizdaikhani: Responsible for patient selection, Collection of clinical data and critical revising for intellectual content; Maryam Sharifian Dorche: Responsible for literature review, Drafting of the initial manuscript, Critical revising for intellectual content; Prad Selvan: Responsible for patient selection critical revising for intellectual content; Benjamin A. Emanuel: Responsible for critical revising for intellectual content; Matthew S. Tenser: Responsible for critical revising for intellectual content; Arun P. Amar: Responsible for critical revising for intellectual content; William J. Mack: Responsible for critical revising for intellectual content

Statement of Ethics

Subject has provided his informed consent for the creation of this manuscript with full knowledge that his clinical findings and treatment are utilized herein for educational and peer-reviewed publication purposes.

Acknowledgements

None.

References

1. Sharifian-Dorche M, Huot P, Osherov M, Wen D, Saveriano A, Giacomini P. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci 2020;399:114085. https://doi.org/10.1016/j.jns.2020.114085.
2. Lodigiani C, Lapichino G, Carenzo L, Ceconi M, Ferrazzi P, Sebastian T. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.
3. Shahjouei S, Naderi S, Li J, Khan A, Chaudhary D, Farahmand G. Risk of stroke in hospitalized SARS-CoV-2 infected patients: a multinational study. E Bio Med 2020;59:102939. https://doi.org/10.1016/j.ebiom.2020.102939.
4. Fara MG, Stein LK, Skliut M, Morgello S, Fifi JT, Dhamoon MS. Macrothrombosis and stroke in patients with mild Covid-19 infection. J Thromb Haemost 2020 28. https://doi.org/10.1111/jth.14938.
5. Oxley T, Mocco J, Majidi S, Kellner C, Shoira H, Singh P, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med 2020;382(20):e60.
6. Shabibabrihami B, Borhani-Haghighi A, Haseli S, Mowla A. Cerebral venous sinus thrombosis might be under-diagnosed in the COVID-19 era. eNeurologicalSci. 2020;15:20:100256. https://doi.org/10.1016/j.jns.2020.100256.
7. Vahabizad F, Sharifian Dorche M, Mohammad P, Khaitibi K, Mowla A. COVID-19-related acute ischemic stroke in young adults: what is the optimal antithrombotic regimen for secondary prevention? J Neurol Res. 2020;000 (000). 000–000 https://doi.org/10.14740/jnr616.
8. Umapathi T, Kr AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, et al. Large artery ischemic stroke in severe acute respiratory syndrome (SARS). J Neurol 2004;251(10):1227-1231.
9. Yaghi S, Ishida K, Torres J, Mac Groy B, Raz E, Humbert K, et al. SARS-CoV-2 and stroke in a New York Healthcare System. Stroke 2020;20. STROKEAHA120030335.
10. Escalard S, Maier B, Redjem H, Delvoye F, Hébert S, Smaida S, et al. Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris. Stroke 2020 29. STROKEAHA120030574.